NCT04024332View on ClinicalTrials.gov

Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 24, 2019

Primary Completion Date

August 14, 2020

Study Completion Date

August 14, 2020

Conditions
Renal InsufficiencyHealthy
Interventions
DRUG

ACT-541468

ACT-541468 25 mg; administered orally

Trial Locations (1)

81241

APEX GmbH, München

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY

NCT04024332 - Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects | Biotech Hunter | Biotech Hunter